8 completed, 2 terminated, 2 unknown, 2 withdrawn. 8 Phase 2, 4 Phase 1, 3 Phase 3, 2 Not applicable, 2 Phase 4.
Follow Omega-3-Acid Ethyl Esters: new trials by email Literature Review of Omega-3-Acid Ethyl Esters trials Research Report on Omega-3-Acid Ethyl Esters
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction Biospecimen Collection, Mammography, Omega-3-Acid Ethyl Esters - Breast Atypical Hyperplasia, Breast Carcinoma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 66 | 2025-07-28 | 2026-08-04 |
| Immunonutrition for Diabetic Foot Ulcers Lovaza, L-Arginine Powder, Vitamin C - Diabetes Mellitus, Diabetic Peripheral Neuropathy | Phase 2 / Phase 3 | Terminated | Prisma Health-Midlands | 1 | 2023-02-08 | 2024-12-27 |
| Phase II Trial to Modulate Intermediate Endpoint Biomarkers in Former and Current Smokers Curcumin C3 complex®, Lovaza®, Placebo - Lung Diseases, Lung Cancer, Protection Against | Phase 2 | Active not recruiting | H. Lee Moffitt Cancer Center and Research Institute | 19 | 2019-06-05 | 2026-02-27 |
| QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 Therapy Avelumab, Bevacizumab, Capecitabine - Melanoma | Phase 1 / Phase 2 | Withdrawn | ImmunityBio, Inc. | 2017-12-01 | 2025-02-21 | |
| QUILT-3.045: NANT Merkel Cell Carcinoma (MCC) Vaccine: Combination Immunotherapy in Subjects With MCC Who Have Progressed on or After PD-L1 Therapy Avelumab, Bevacizumab, Capecitabine - Merkel Cell Carcinoma | Phase 1 / Phase 2 | Withdrawn | ImmunityBio, Inc. | 2017-12-01 | 2025-02-21 | |
| A Study to Investigate How Common Pancreatic Exocrine Insufficiency (PEI) is in Patients With Type 2 Diabetes and Also to Investigate the Uptake of a Single Dose of EPANOVA® or OMACOR® in Patients With Different Degrees of PEI Epanova® (omega-3 carboxylic acids), Omacor® (omega-3-acid ethyl esters) - Diabetes Mellitus, Type 2, Exocrine Pancreatic Insufficiency | Phase 2 | Completed | AstraZeneca | 490 | 2015-03-01 | 2017-01-20 |
| COGNUTRIN in Breast Cancer Survivors VitaBlue™, Placebo, Lovaza® - Breast Cancer | Early Phase 1 | Completed | H. Lee Moffitt Cancer Center and Research Institute | 36 | 2014-07-30 | 2020-07-14 |
| Effects of Dietary Omega-3 Fatty Acids on Reproductive Hormones in Obese Women LOVAZA, GnRH - Obesity, Fertility | Not applicable | Completed | University of Colorado, Denver | 39 | 2014-07-01 | 2017-02-02 |
| Interaction of Epanova on Warfarin Pharmacokinetic and Anticoagulant Activity and Comparison of the Effects of Epanova and Lovaza on Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA) After Low-fat Meals warfarin, omefas, omega-3-acid ethyl esters - Hypertriglyceridemia | Phase 1 | Completed | AstraZeneca | 52 | 2011-08-01 | 2015-04-24 |
| Effects of Omega-3 EPA/DHA for Soldiers at Risk for Mood Disorders Lovaza, omega-3 fatty acid ethyl ester, Placebo, visually identical to Lovaza - Mood Disorders, Depression | Phase 2 | Unknown | United States Department of Defense | 256 | 2010-11-01 | 2011-03-09 |
| Fish Oil Study for High Triglyceride Levels in Children Omega-3-acid ethyl esters, Placebo - Hypertriglyceridemia | Phase 2 / Phase 3 | Completed | Babu Balagopal | 42 | 2009-07-01 | 2022-11-08 |
| Triglyceride Lowering Study Omega-3-Acid Ethyl Esters - Hypertriglyceridemia | Phase 4 | Unknown | Jewish Hospital, Cincinnati, Ohio | 25 | 2009-07-01 | 2009-07-08 |
| Study of Fish Oil to Reduce ALT Levels in Adolescents Omega-3-acid ethyl esters, Placebo - Non-alcoholic Fatty Liver Disease, Fatty Liver | Phase 1 | Terminated | Boston University | 3 | 2008-06-01 | 2016-01-29 |
| An Open-label Extension to Assess the Continued Efficacy of Omacor Plus Simvastatin Omacor + simvastatin - Dyslipidemias | Phase 4 | Completed | Provident Clinical Research | 17 | 2007-08-01 | 2025-05-29 |
| A Pilot Study of Eicosapentaenoic Acid (EPA) in Patients With Cancer Cachexia Eicosapentaenoic Acid - Cancer Cachexia | Not applicable | Completed | H. Lee Moffitt Cancer Center and Research Institute | 36 | 2007-07-01 | 2017-03-23 |
| Evaluation of Efficacy and Safety of Lovaza (Omega-3-Acid Ethyl Esters) in Recurrent, Symptomatic Atrial Fibrillation omega-3-acid ethyl esters, Placebo - Fibrillation, Atrial | Phase 3 | Completed | GlaxoSmithKline | 663 | 2006-11-01 | 2017-01-30 |
Hypertriglyceridemia (3) · Breast Neoplasms (2) · Atrial Fibrillation (1) · Breast Carcinoma In Situ (1) · Carcinoma, Intraductal, Noninfiltrating (1) · Carcinoma, Merkel Cell (1) · Combat Disorders (1) · Depression (1) · Diabetes Mellitus (1) · Diabetes Mellitus, Type 2 (1) · Diabetic Foot (1) · Dyslipidemias (1) · Exocrine Pancreatic Insufficiency (1) · Fatty Liver (1) · Hyperlipoproteinemia Type IV (1)
H. Lee Moffitt Cancer Center and Research Institute (3) · AstraZeneca (2) · ImmunityBio, Inc. (2) · Babu Balagopal (1) · Boston University (1) · GlaxoSmithKline (1) · Jewish Hospital, Cincinnati, Ohio (1) · National Cancer Institute (NCI) (1) · Prisma Health-Midlands (1) · Provident Clinical Research (1) · United States Department of Defense (1) · University of Colorado, Denver (1)
United States (11) · Denmark (1) · Hungary (1) · Iraq (1) · Latvia (1) · Poland (1) · Slovakia (1) · Sweden (1)
Nagi Kumar, Ph.D. (2) · Alex Polotsky, MD, MS (1) · Carine M Lenders, MD, MS, ScD (1) · Charles Glueck, MD (1) · Daniel T Johnston, MD, MPH (1) · J. Benjamin Jackson, MD (1) · Kevin C. Maki, PhD (1) · Lauren Nye (1) · Michael H Davidson, MD, FACC (1) · Nagi Kumar, Ph.D (1) · Samuel Gidding, MD (1)
PMID 19619690, PMID 21078810, PMID 21297494, PMID 26523525, PMID 29802077, PMID 30773100
2014 (1), P30CA046592 (1), U54HD058155 (1), UG1CA242632 (1)